Chronic obstructive pulmonary disease * 12: New treatments for COPD
Open Access
- 1 September 2003
- Vol. 58 (9) , 803-808
- https://doi.org/10.1136/thorax.58.9.803
Abstract
Drugs currently available or under development for the treatment of chronic obstructive pulmonary disease (COPD) are reviewed. More research on the basic cellular and molecular mechanisms of COPD and emphysema is urgently needed to aid the logical development of new treatments for this common and important disease for which no effective preventative treatments currently exist. There is a major need to develop new treatments for chronic obstructive pulmonary disease (COPD), as no currently available drug therapy reduces the relentless progression of the disease. In particular, there is a need to develop drugs that control the underlying inflammatory and destructive processes. There have been few therapeutic advances in the drug treatment of COPD, in contrast to the enormous advances made in asthma management which reflect a much better understanding of the underlying disease.1–3 Although COPD is commonly treated with drugs developed for asthma, this is often inappropriate as the inflammatory processes in the two conditions differ markedly.4,5 Recognition of the global importance and rising prevalence of COPD and the absence of effective treatments has now led to a concerted effort to develop new drugs for this disease.6,7 Rational treatment depends on understanding the underlying disease process and there have been recent advances in understanding the cellular and molecular mechanisms that may be involved. COPD involves a chronic inflammation in the small airways and lung parenchyma with the involvement of neutrophils, macrophages, and cytotoxic (CD8+) T lymphocytes. This inflammation results in fibrosis with narrowing of the small airways (chronic obstructive bronchitis) and lung parenchymal destruction due to the action of various proteases such as neutrophil elastase and matrix metalloproteinases (emphysema). This inflammation is quite different from that seen in asthma, indicating that different treatments are likely to be needed.4 There are several reasons why drug …Keywords
This publication has 83 references indexed in Scilit:
- The New Phosphodiesterase 4 Inhibitor Roflumilast Is Efficacious in Exercise‐Induced Asthma and Leads to Suppression of LPS‐Stimulated TNF‐α Ex VivoThe Journal of Clinical Pharmacology, 2002
- Enhanced neutrophil response in chronic obstructive pulmonary diseaseThorax, 2001
- p38 MAP kinase and MKK‐1 co‐operate in the generation of GM‐CSF from LPS‐stimulated human monocytes by an NF‐κB‐independent mechanismBritish Journal of Pharmacology, 2000
- Regular review: Effectiveness of interventions to help people stop smoking: findings from the Cochrane LibraryBMJ, 2000
- InfliximabDrugs, 2000
- The Biology of Chemokines and their ReceptorsAnnual Review of Immunology, 2000
- INHIBITION OF NITRIC OXIDE SYNTHASE AS A POTENTIAL THERAPEUTIC TARGETAnnual Review of Pharmacology and Toxicology, 1999
- Tiotropium (SPIRIVA™): Mechanistical considerations and clinical profile in obstructive lung diseaseLife Sciences, 1999
- EtanerceptDrugs, 1999
- ONO-5046, a novel inhibitor of human neutrophil elastaseBiochemical and Biophysical Research Communications, 1991